FDA Cites Akorn for Contamination Protections, Aseptic Processing

Drug Industry Daily
A A
The FDA hit Akorn with a lengthy Form 483 with 13 observations for failing to properly safeguard against microbiological contamination and to monitor conditions in aseptic processing areas following April/May inspections of its Decatur, Illinois, facility.

To View This Article:

Login

Subscribe To Drug Industry Daily